Ekene Enemchukwu, MD
Urogynecology and Reconstructive Pelvic Surgery · Stanford, CANPI 1750558193
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Boston Scientific at 48.8% of the total. Reporting peaked in 2023 at $6,761 and has fallen 94.7% since, to $357 in 2025.
Across 52 payments — averaging $288.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$7K
- AbbVie$4K
- Urovant Sciences Inc$2K
- Medtronic$1K
- Bluewind Medical$173
- Coloplast$136
- plus $42 from 2 others
Across 21 payments — averaging $930.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urovant Sciences Inc$17K
- Sumitomo Pharma America, Inc.$3K
What the payments were for
- Consulting fees$7,95053%
- Speaking & faculty fees$5454%
- Travel & lodging$4,69031%
- Food & beverage$1,82012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 16 | $7,324 |
| AbbVie | 7 | $3,609 |
| Urovant Sciences Inc | 12 | $2,426 |
| Medtronic(2 entities) | 10 | $1,293 |
| Bluewind Medical | 2 | $173 |
| Coloplast | 3 | $136 |
| Axonics, Inc. | 1 | $25 |
| Ambu Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$3,412
- GEMTESA$2,126
- INTERSTIM$1,152
- GENERAL FEMALE SUI$500
- REVI$148
- GENERAL - THERAPIES$143
How this compares
$15,004 in reported general payments places this provider in the 80th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 24 | $23,728 |
| MyrbetriqMirabegron | 16 | $11,404 |
| Estradiol | 26 | $1,827 |
| Finasteride | 12 | $198 |
| Cephalexin | 13 | $65 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Stanford
- Andrew BrillSan Francisco$345K
- Bilal KaakiRiverside$301K
- Savitha KrishnanMountain View$243K
- Peter CastilloLos Gatos$95K
- Bruce Kahnla Jolla$79K
- Jennifer GruenenfelderOrange$76K
- Traci ItoSan Francisco$68K
- Tanaz FerzandiLos Angeles$60K
- Sadikah BehbehaniCosta Mesa$53K
- Christopher TarnayLos Angeles$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.